All In Biotech

Drug Trial Radar · NCT05205850

A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors with Positive Expression of Claudin 18.2

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Mar 3, 2022

Primary completion

Sep 30, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。

Conditions

  • Advanced Solid Tumor

Interventions

  • RC118-ADCDrug

    RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: 28 days after first treatment.
  2. The incidence and severity of adverse events (AE)Time frame: From the day of ICF sign to 28 days after the day of the last treatment
  3. Objective response rate (ORR)Time frame: 15 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • The first affiliated hospital, zhejiang universtity school of medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.